Victory Capital Management
CERE

Victory Capital Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Victory Capital Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,317
Closed -$463K – 2542
2024
Q2 		$463K Sell
11,317
-138
-1% -$5.75K ﹤0.01% 2001
2024
Q1 		$484K Sell
11,455
-137
-1% -$5.75K ﹤0.01% 1992
2023
Q4 		$492K Buy
+11,592
New +$333K ﹤0.01% 2005
2023
Q3 		– Sell
-7,377
Closed -$235K – 2575
2023
Q2 		$235K Buy
+7,377
New +$226K ﹤0.01% 2170
2023
Q1 		– Sell
-7,601
Closed -$240K – 2709
2022
Q4 		$240K Sell
7,601
-10,192
-57% -$288K ﹤0.01% 2224
2022
Q3 		$503K Sell
17,793
-1,685
-9% -$50.2K ﹤0.01% 2054
2022
Q2 		$515K Buy
19,478
+1,994
+11% +$56.6K ﹤0.01% 2040
2022
Q1 		$512K Buy
17,484
+9,596
+122% +$280K ﹤0.01% 2115
2021
Q4 		$256K Buy
+7,888
New +$278K ﹤0.01% 2424

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Victory Capital Management's CERE Position: Q3 2024 in Review

Victory Capital Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 11,317 shares — an estimated $463K sold.

Victory Capital Management first reported a position in CERE in Q4 2021 and held it in 9 quarters. The position peaked at $515K in Q2 2022. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Victory Capital Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Victory Capital Management sold 11,317 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $463K.
  • Victory Capital Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
  • Victory Capital Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $515K in Q2 2022.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Victory Capital Management's 13F filing for Q3 2024, filed 5 Nov 2024.